text:
[Skip to content]
In 2014, we are planning to redevelop Private Healthcare UK and its sister site GoPrivate.com into a single site.
Your opinion is important to us, and so we are asking for your help to test the search we'll be using for finding a doctor, hospital, clinic or other health professional.
The task will take less than a minute to complete, and you will be entered into a prize draw with the chance to win £100 of Amazon vouchers!
Start now >
This site complies with the HONcode standard for trustworthy health information: verify here.
Mr George Fayad is Lead Rhinologist and Chairman of the ENT department at Basildon and Thurrock University Hospitals NHS Foundation Trust. He provides private treatment for nasal conditions at a number of independent hospitals in London and Essex:
Extensive trained in Europe and the USA, Mr Fayad is an experienced and innovative rhinologist, most recently pioneering the Breathe titanium nose implant for the treatment of breathing problems in patients with nasal valve collapse. Actively involved in research, his interests include nasal problems during pregnancy, asthma, nasal allergic polyps and new treatments for snoring. He is an expert on allergy and allergic rhinitis, and was responsible for setting up the multidisciplinary unit for patients suffering from a combination of nasal polyps, allergy and asthma at Basildon University Hospital, one of the first of its kind in the UK.
Mr Fayad offers expert management and treatment for all conditions affecting the nose, including:
Situated in the area corresponding to the crease on each side of the nose, the nasal valve is the narrowest part of the nasal airway. On exertion, during exercise for example, the increased air pressure tends to cause the lateral nasal walls to collapse inwards, nearly closing off the airway, however in people with nasal wall collapse this valve closes off completely, producing the symptoms of a blocked nose and difficulty breathing.
The Breathe-Implant is a small 0.5mm thick triangular-shaped piece of titanium that is positioned between two layers of cartilage in the nose to hold the nasal valve area open. First performed in the UK in 2009 by Mr Fayad, the procedure is associated with significant and quantifiable improvements in breathing. Patients also report improvements to their sense of smell, a reduced incidence of headaches and a reduction in snoring.
Date of Registration: 3 Jul 1997
Mr George Fayad is an accredited consultant for the UK's leading private healthcare providers and private hospitals, including Spire Healthcare
Intuition Communication Ltd bears no responsibility for information published on this website, which concerns or relates to advertisers and their products and services. Read Disclaimer in full.
For private patient appointments, please contact Mr Fayad's private secretary Sheila Jefferys on:
Tel: 01277 695689
Fax: 01277 204518
Mobile: 07704 046 909
Email: email@example.com
Website: www.entsurgeonessex.co.uk
Balloon sinuplasty
Titanium Breathe-Implant
Surgery for snoring and sleep apnoea
American Academy of Otolaryngology
Royal College of Surgeons of England
Basildon University Hospital, Nethermayne, Basildon, Essex, SS16 5NL
Tel: 0845 155 3111
Spire Hartswood Hospital
Eagle Way
Essex CM13 2LE
Essex Nuffield Brentwood Hospital
Shenfield Road
Essex CM15 8EH
The Harley Street Clinic
100 Harley Street
London W1G 7JA
The Princess Grace Hospital
42-52 Nottingham Place
London W1U 5NY


text:
Roy Jackson
Roy Jackson was a partner in ownership of Barbaro with his wife Gretchen Jackson. Roy and Gretchen met in high school and both attended the University of Pennsylvania.
Roy has always been involved in sports. In college he was a 3 sport star athlete who's sports career was cut short his sophomore year because of a heart condition. His surgery and recovery delayed his graduation by 2 years.
Roy Jackson has spent much of his life in the game of baseball, serving from 1983-2000 as president of Convest, Inc., a firm that represented professional ballplayers that included Edgar Martinez and Jorge Posada. He also served as past president of minor league baseball leagues such as the International League (AAA), Pacific Coast League (AAA) and Eastern League (AA). As a club owner, he formerly owned minor league teams in York, Pa. (Pirates) and Tucson, Ariz. (Toros)
Mr. Jackson's father, Roy Sr., passed away when Roy was eight, and was involved with horses and was a renowned breeder of foxhounds. Later, his mother and stepfather owned racehorses, introducing him to the game more deeply in the 1950s.
Roy and Gretchen Jackson's Lael Stables began about 30 years ago.
article about the Jackson's and Roy's involvement with many sports

subset: commoncrawl


text:
Channel 6 News - Search Results
Big milestone for $61M Golub Center for Emergency Care at Ellis Hospital
SCHENECTADY -- A big milestone was celebrated at the new Golub Center for Emergency Care in Schenectady on Thursday.
A ceremony was held for the signing of the final beam for the emergency department project at Ellis Hospital.
The $61 million project began in 2012. When it's completed, the Golub Center will have 62 private rooms, eight crisis rooms and an express care area to treat less serious patients.
The project is scheduled to be finished in early 2015.


text:
- Retrieving data. Wait a few seconds and try to cut or copy again.
Posts Tagged 'FLEXTab'
It's better to give and receive: Rogers launches Refer Your Friends program
When I really love a restaurant, movie or service, I tell all of my friends and family about the great experience I had. Sometimes that includes sharing it on my social profiles like – Twitter, Facebook, or Linkedin. But what if sharing with your friends and family actually rewarded you beyond a few likes?
With our new Refer Your Friends program, when you refer someone to Rogers and they sign up for a wireless plan with minimum 2 year FLEXtab agreement, you both get up to a $25 bill credit. The more friends you refer the more you can earn. You could receive up to $300 a year.
Here's how to start giving and receiving:
- As a Rogers wireless customer go to rogers.com/refer to register for the program and read the terms and conditions
- Share the offer with your contacts via email, social media or word-of-mouth
- When your friend receives the offer, they simply go to rogers.com/refer to register
- Friends can check out Rogers devices and plans online or go to their nearest store location to purchase their new wireless plan with a minimum 2-year FLEXtab agreement
- The friend you referred must go back to rogers.com/refer to enter in their profile, their mobile telephone number on their new plan
- Both you and your friend will now get up to $25 in savings
The holidays are coming and who couldn't use a little extra cash in their pocket? Start encouraging your friends to pick up one of the great new LTE superphones available at Rogers like the Nokia Lumia 920, Motorola RAZR HD LTE or the LG Optimus G 2600.
What device will you recommend to your friends and family?
Katie is a regular contributor to Redboard
Are you a commitment phobe? We've got just the thing for you!
You're too young to settle down. Sure, you've had some great times with good old reliable, but you miss the thrill and excitement that comes with something totally new.
We get it. With the amazing selection of devices available today and the next wave of cool smartphones always around the corner, we know you want to get your hands on the latest and greatest when YOU want it, without waiting until the end of your term.
We agree. That's why as of today, customers who sign up with Rogers have a new way to get the coolest smartphones without having to wait until the end of their term. So, what is it? It's called FLEXtab. Here's how it works:
- Choose a smartphone with an eligible term plan and make a low payment on the device – the price will depend on the device you choose, but we'll spot you the majority of the upfront full device cost. The remaining amount is your FLEXtab balance.
- Every month into your term, your remaining FLEXtab balance goes down.
- Want to get a new smartphone? Just pay off your FLEXtab balance and you'll be eligible to upgrade to the device you want.
It really is that simple. Super easy, all done on your terms, not ours, and is part of our commitment to giving you even greater flexibility and choice. Find out more at www.rogers.com/flextab.
So tell us, what do you think of FLEXtab?
Carly is a regular contributor to RedBoard


text:
ACIG Home
ACIG Journal
ACIG Books
ACIG Forum
ACIG Special Reports
ACIG Database
ACIG Books, Articles & Media
Indian-Subcontinent Database
Indochina Database
Far-East Database
LCIG & NCIG Section
All Categories
ACIG Special Reports
ACIG Database
ACIG Books, Articles & Media
Indian-Subcontinent Database
Indochina Database
Far-East Database
LCIG & NCIG Section
Advanced Search
Contributors Log-in
ACIG Special Reports
Aero India 2003 - Part 6
By B Harry
Sep 16, 2003, 03:13
Email this article
Printer friendly page
A HAL Dhruv (IA-1105) of the Indian Army. The year 2002 saw the delivery of 12 Dhruv helicopters to the armed forces. The Indian Army's operational trials of the type was the most stringent, with flights at temperatures ranging from 45� C to sub-zero at 19,000 ft.
IAI's modified export standard Dhruv (not pictured) features a modular avionics package including a core avionics computer, a full glass cockpit with four interchangeable MFDs, INS-GPS navigation, an EW suite with LWR, RWR, MAWS and automatic countermeasures dispenser, digital moving map and a Helicopter Multi-Mission Optronic Stabilised Payload (HMOSP) sensor package consisting of a daytime CCD camera, a laser rangefinder and FLIR mounted in a gimballed payload assembly. HAL also offer the Dhruv with their own avionics package for customers who do not opt for the Israeli one.
A HAL Jaguar-IS (JS-131) armed with overwing Matra Magic-II AAMs and a GBU-24 Paveway-III LGB on the centerline. Jaguars were among the first to receive RCS reduction through RAM coating and structural modifications. In the mid-90s, IAF Jaguars saw the first inflight-refueling trials with RAF VC-10s which were taken on loan.
IAF Jaguars are in the process of being upgraded to 4th generation standards in order to keep the fleet viable till 2020.
LRDE (DRDO) revealed it's recently developed Weapons Locating Radar (WLR) for the first time. The system is a spin-off of the Phased Array Radar technology development for the 'Rajendra' radar. Configured on a wheeled vehicle and designed to operate in a high-density fire environment, the WLR has all weather capability, high mobility and quick reaction time.
Another one of LRDE's major products is the 3D Central Acquisition Radar (CAR). It is capable of handling 150 targets in Track-While-Scan (TWS) mode and a detection range of more than 150 km at 7.5 rpm. It is designed to operate in heavy ECM environments and features extensive system BITE with independent BITE for the antenna. 3D-CAR is an integral part of the Akash air-defence system.
A CABS (DRDO) Bheema aircraft loading trolley holds an ARDE (DRDO) 450 kg High Speed Low Drag (HSLD) bomb. The bomb is effective against larger targets such as railway yards, runways and hardened bunkers. The well known Brahmos supersonic cruise missile and the Prithvi SRBM are visible in the background.
The IAI Elta EL/M-8826 portable tactical terminal receives and processes real time data from UAVs and/or surveillance radars mounted on Balloons. The latter are an important part of IAI Elta's integrated border protection system.
Bharat Electronics (BEL) is India's leading defence electronics manufacturer. Responsible for the manufacture and production of DRDO designed and developed systems, BEL also boasts of 350 different products of it's own. BEL's turnover last year stands at Indian Rs.19.4 billion with a net profit of Rs.2 billion.
BEL offer an upgrade to the elderly Bofors L-60 gun. All hydraulic parts have been replaced by electrical/electromechanical systems and an integrated FCS and an optronic sight have been added. It also features a Belgian BARCO AMLCD display and voice/visual communication.
BEL's 'Reporter' Tactical Control Radar is an early warning, alerting and cueing system that also includes weapon control functions. This highly mobile system features clutter suppression and high resolution.
BEL's first LPI radar prototype for the Indian Navy. BEL is also upgrading the old Shilka self propelled air defence system in cooperation with the 50th Army Base Workshop. The Ku band fire-control radar will receive a new transmitter with updated receiver, signal processing unit, radar computer, weapons computer, PPI display and commander's display console. Optronic units, a datalink and a cabin airconditioner have also been added. The system will also have a new Hindustan Powerplus Caterpillar diesel engine of 280 hp at 2000 rpm.
© Copyright 2002-3 by ACIG.org
Top of Page
ACIG Special Reports
al-Ain Show, January 2006
Rheine-Hopsten Airbase Fly-Out
Eskisehir Calling!
The Kish Trade Fair Fails to Realize Expectations
Hellenic Air Force Open Day 2004 Tanagra - Souda
Base Visit: "Fluglehrzentrum F-4": Hopsten AB, Germany
Arrival of F-5Es in Austria
Hellenic Air Force Open Day 2004, Elefsina-Tatoi
DEFEXPO 2004 - Part 12
DEFEXPO 2004 - Part 11
DEFEXPO 2004 - Part 10
DEFEXPO 2004 - Part 9
DEFEXPO 2004 - Part 8
DEFEXPO 2004 - Part 7
DEFEXPO 2004 - Part 6
DEFEXPO 2004 - Part 5
DEFEXPO 2004 - Part 4
DEFEXPO 2004 - Part 3
DEFEXPO 2004 - Part 2
DEFEXPO 2004 - Part 1
DEFEXPO 2004 Introduction
CIAF 2002 Airshow Report
ICAS 2003 Report - Part 5
ICAS 2003 Report - Part 4
ICAS 2003 Report - Part 3
ICAS 2003 Report - Part 2
ICAS 2003 Report - Part 1
Aero India 2003 - Part 12
Aero India 2003 - Part 11
Aero India 2003 - Part 10
Aero India 2003 - Part 9
Aero India 2003 - Part 8
Aero India 2003 - Part 7
Aero India 2003 - Part 6
Aero India 2003 - Part 5
Aero India 2003 - Part 4
Aero India 2003 - Part 3
Aero India 2003 - Part 2
Aero India 2003 - Part 1
Aero India 2003 Introduction
Highlights from IDEAS 2002


text:
Channel 6 News - Search Results
Police have identified suspect in pellet gun shooting of mail carrier
SCHENECTADY - Schenectady Police and the US Postal Inspection Service have identified a suspect in a pellet gun shooting.
Police say the incident happened last Thursday, when a mail carrier was struck with a pellet that was allegedly fired from a pellet gun on Van Vranken.
Residents were informed they could pick up their mail at the Schenectady Post office after delivery was suspended to over 40 buildings, some affecting multiple families.
Police have not released the name of the suspect.
The US Postal Service plans to resume mail delivery service on Friday.


text:
Could it be that plain old mental habit is the reason for gender inequality at work? According to consultant and former businesswoman Caroline Turner, that's pretty much what it comes down to. In a blog post for the Huffington Post, Turner said that the biggest reason women aren't proportionately represented in business leadership positions is a set of "mind-sets," or unconscious ways of viewing the world. The most powerful and deep-rooted of these mind-sets, it seems, is the "double bind," or the idea that if a woman channels her more feminine energies, she'll be liked by her coworkers but not seen as a leader. On the other hand, if she allows her masculine energies to lead the way, she's likely to be judged and disliked. What I take this to mean is that the biggest obstacle we're up against in the workplace is essentially subconscious stereotyping. Keep reading »
Zergnet: Simply Irresistible
- Popular


text: No recent wiki edits to this page. Bruce Wayne has done the impossible and survived against all odds. Not back in the present, he must get his affairs in order and set things in motion before the launch of his newest crime fighting venture, Batman Incorporated!Collected in Batman and Robin: Batman and Robin Must Die! and Batman and Robin: The Deluxe Edition Vol. 3.


text:
Update 5
Both trenches are now up and running. Mark Lodwick's is producing burials in addition to the defensive wall and ditch he already has to deal with. Mark Lewis' is just beginning but hopes are high that it contains the defensive wall around the site.
"The past two days have produced several surprises - all welcome. We have had excellent digging weather, contrary to the forecast, and just before lunch Mark Lodwick and his team uncovered the leg bones of another burial in his trench. An interesting feature of this new burial is that the head lies to the north, whereas the burials found previously have lain with heads to the south.
The new burial, possibly that of a young adult, lies at a similar depth to the others, and was also laid to rest in the upper fills of our enclosure ditch.
The cleaning of the 1998 cross-section across the ditch at this point has also revealed the crushed skull of another infant, again orientated north-south, with head to south. These finds are very important and our speculation on the backgrounds of the burials continues."
"A brilliant couple of days and a great team, we've all put in a lot of hard work, but its worth it when we take a step back to see the results.
Yesterday the whole team spent the day emptying out the soil that got filled in to the part of the trench that was excavated last year. By the end of the day we'd emptied out the ditch beside the enclosure wall and come down on top of a human burial which we located last year but left unexcavated.
As well as all this, we uncovered a new part of the wall not seen for a thousand years and located a possible fragment of a human skull in a section we've cut across the ditch. The leg bones of yet another skeleton have also been found although much of this latest example probably lies outside our trench - so we've had to open a bigger area to catch the rest.
Today a smaller team have been busy exposing a rubble spread that butts against the outside of the enclosure wall and which may have more burials beneath it.
All very exciting - and we've still only been digging for four days!"
"Until yesterday I've been helping to get Mark Lodwick's trench cleaned up, but now I've started work on my own. The bulk of the ploughsoil was removed with a mechanical digger and we quickly spotted several large stones in a line - another section of our enclosure wall? The area of the trench is very boggy and Roger - the farmer - tells us that he's made many attempts to drain the area. We've also found a lot of broken drainage pipe in the exposed area.
Most of today has been spent tidying up the trench - straightening the sides and removing the lumps left behind by the digger. This has taken most of the day as the trench is about 400m square! Fortunately we'll only be excavating an L-shaped area within this.
By the end of the day we had cleaned a part of this L-shape, finding a grey clay layer beneath the ploughsoil. Next we'll be looking at the area around the stones to see if they really are the remains of the enclosure wall. "
"I've now got the finds hut completely ready to process the finds from the dig. The first few days of work, however, never produces many finds as the time is spent cleaning the remainder of the ploughsoil to get to the archaeology. I've therefore spent most of my time on site. A few days of manual work makes a nice change, and an extra pair of hands is always welcome in the trenches.
The finds I have had to process so far have mostly come from the metal detectoring of the ploughsoil: a scrap of copper, bits of lead, and two iron knife blades - to go with the large number of similar blades found in previous years. Their find spots have been marked for later plotting onto our site plan.
All metal finds are recorded and packaged up for return to the museum - cleaning metals requires trained conservators and the facilities of a conservation lab, neither of which we have on site. "


text:
Your cart is empty!
NasaFlo Neti Pot is a natural soothing saline nasal wash. Neti pots have been around for thousands of years, mainly used by yoga enthusiasts. The neti pot is an excellent way to clean mucus from the nose making medication more effective. They also clean allergens, irritants, bacteria and viruses from the nose reducing the frequency of infection. Furthermore, they help decrease swelling in the nose and increase air flow. NasaFlo Neti Pot is excellent for all ages.
NasaFlo Neti Pot helps alleviate..
Do not rinse if nasal passage is completely blocked or if you have a new ear infection, ear pain or blocked ears. If you have had recent ear or sinus surgery, please contact your physician prior to irrigation. If you experience any pressure in the ears, stop irrigation and get further directions from your physician. For non-emergency questions, please contact our office. Please read enclosed brochure for more details. Store or keep in a cool and dry place.
Preffered Plus cough formula DM expectorant syrup, alcohol free - 4 oz
Our Price:$1.95
Simply Saline Sterile Nasal Mist, Super Size - 3 oz
Our Price:$4.90
Boericke and Tafel Kali bichromicum 30C tablets - 100 ea
Our Price:$3.47
Natural Medicine fragrances and phenolics allergy relief homeopathic spray - 2 oz
Our Price:$11.69
Natural Medicine dust mite and roach allergy relief homeopathic spray - 2 oz
Our Price:$13.25
Natural Medicine rocky mountain U.S. homeopathic region allergy relief - 2 oz
Our Price:$11.60
Product descriptions and images presented on the site are for representational use only and do not constitute or substitute for medical information from your health care or medical professional. Information on this site is provided for informational purposes only. You should read carefully all on correct product packaging and follow the instructions. If you have or suspect that you have a medical problem, promptly contact your health care provider. Information and statements regarding dietary supplements on this site have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease and may be for commercial. Image shown for reference only. Actual item you recieve may differ from shown.


text:
She was preceded in death by her parents, Charlie and Mae Bell Seaborn Cofer; and husband, Horace Monroe Gibson.
She is survived by her daughter, Pam Higgins of Cleveland; two grandchildren; and several nieces and nephews.
The funeral will be held at 2 p.m. today, Dec. 5, 2012, at Grissom Funeral Home with the Rev. Anthony Howard officiating. Interment will follow in Sunset Memorial Gardens.


text:
.<quoted text>
yo yo yo,sup man? ahs dun axed mah homeys iffn dey dun copped enny o dem lawn jockeys an dey got only one wat deys be givin me an mah bitch,tarnisha fo a house warmin wen weese dun gits set up in ann arbor.
... me an my wifey gots a sure nuff nice lawn jockey in our ann arbor digs. We got it at a yard sale in 74. I paint it real nice every spring wit dat gloss black spensive paint. What that brass ring before? So the little kallark man can holt da howze? When ya moove there check it out. It is bolted to a slab of cement out where yall can see it every time yo done drives by. Sweet.


text:
จาก โครงการระบบอีเลิร์นนิ่ง มก.ฉกส.
All of us are aware that the Xbox 360 is surely an steeply-priced gaming console system. This really is why you certainly will consider all of the crucial safety measures so as to reduce it from breaking not to mention eliminate other servicing challenges connected to Xbox 360 like the so identified as red ring of dying. So, listed here are a few techniques that could provide help to avert encountering the red ring of dying and in addition make your Xbox 360 gaming console past a whole lot lengthier. The primary element that you just will need to know is the fact the majority of people continue to keep their Xbox 360 inside of a screen cabinet so that you can sustain it outside of harms way. Some do that simply because it appears prettier. On the other hand, it's amongst the most important triggers of overheating, which can lead to the red ring of loss of life and persistent freezing or hanging though enjoying a match. You should have to keep in mind the Xbox 360 generates a considerable amount of warmth, in particular the processors within it. You will want for getting rid in the high temperature and maintain the sport console trendy. So, if you should continue to keep your Xbox 360 within a show cabinet, it might be time for you personally to find it out within the open up. Frequently try to remember that you just have to enable air circulate on all sides within the Xbox 360. By executing this, it will be possible to help keep your gaming console great and forestall the red ring of dying. stop by http://magellantech.obs.carnegiescience.edu/content/could-it-be-functional-so-you-can-get-xbox-no-cost-charge-or-super-budget-friendly to locate out more information concerning xbox 360.
A different preventive preservation methodology that you just can perform to avoid your Xbox 360 from freeing is by inserting the facility brick along with an open up box. It may well audio odd but there's a rational basis for this. You could possibly have observed the strength brick for the Xbox 360 has very little admirers inside of. By positioning it along with an open up box, you'll be able to successfully pump air in and from the facility brick that could retain it wonderful or avoid it from overheating. By carrying out this, it is possible to prevent your online games from continuously freezing. Continually keep in mind you must always maintain your Xbox 360 well-ventilated. By performing so, you can expect to forestall overheating that is the primary reason behind the red ring of demise and freezing. An extra solution would be to always keep the dust away from your Xbox 360. For this, you'll be able to make use of a call cleaner. This could assist in cleansing the delicate elements on the Xbox 360. The get hold of cleaner should be able to do away with dust productively. Often sustain in your mind that if dust accumulates in your Xbox 360, air will not be ready to maintain the parts, mainly the processors, interesting good enough to accordingly perform. By cleansing your Xbox 360 once in a while, you'll be able to maintain it nice and well-ventilated, that could assist in protecting against freezing or perhaps the red ring of demise. These are generally a number of the preventive routine maintenance suggestions for Xbox 360. Usually keep in mind which the right approach to manage the Xbox 360 is by retaining it well-ventilated to circumvent overheating. You are able to do this by actively playing considering the Xbox 360 on open up room, attempting to keep the facility brick well-ventilated, and preserving it no charge from dust. By means of the following pointers, it is easy to make sure that you'll be able to have fun with actively playing with a few for the most fantastic Xbox 360 video games for numerous a great deal more many years to return. Visit Website for further resources on xbox 360.


text:
Revisions to these Guidelines
About The EMBO Journal
Editorial Policies
- Authorship Guidelines
- Use of Living Organisms
- Animal welfare
- Human subjects
- Biosecurity
- Availability of Published Material and Data
- Conflicts of Interest
- Scientific Integrity
- Data Collection and Presentation
- Originality & Plagiarism
- Embargo Policy
- Citation
- Editorial Process
- Transfer Policies
Manuscript Preparation
- General Guidelines for Submission
- Manuscript Format
- Text
- Unpublished Data
- Conventions and Abbreviations
General Formatting Guidelines
- Text
- Figures
- Data Presentation
- Tables
- References
- Expanded View (replaces Supplementary Information)
- Data Deposition
For Acceptance and Publication
- Speed of Publication
- Proofs
- Press Embargo
- Charges
- Open Access & Self Archiving
- Author Licence Agreement
- Digital Object Identifier
Help and Contact
About the Journal
Aims and Scope
Launched in 1982, The EMBO Journal is an international print and online publication dedicated to rapid publication of research papers in all areas of molecular biology. The Journal is one of four journals owned and run by the European Molecular Biology Organization (EMBO) and published through EMBO Press with support from Wiley and HighWire Press.
The EMBO Journal publishes full-length papers describing original research in all areas of molecular biology, with an emphasis on mechanistic insight and physiological significance. Manuscripts will be selected on the basis of conceptual advance, general interest and technical quality.
As a guide, the journal welcomes submission of articles on the following biological processes, investigated at any level of organization (from the structural and molecular through to the organismal) and in any model system (including plants and micro-organisms):
- Ageing
- Autophagy
- Cancer
- Cell Adhesion, Polarity & Cytoskeleton
- Cell Cycle
- Cell Death
- Developmental Biology
- DNA Replication, Repair & Recombination
- Chromatin, Epigenetics & Genomics
- Immunology
- Membrane & Intracellular Transport
- Metabolism
- Microbiology, Virology & Host Pathogen Interaction
- Molecular Biology of Disease
- Neuroscience
- Plant Biology
- Post-translational Modifications, Proteolysis & Proteomics
- RNA Biology
- Signal Transduction
- Stem Cells
- Structural Biology
- Systems, Chemical & Computational Biology
- Transcription
- Protein Biosynthesis & Quality Control
- Vascular Biology
For papers submitted from January 2009 onwards, The EMBO Journal will make the editorial process transparent for all accepted manuscripts by publishing as an online supplementary document containing all correspondence between authors and the editorial office relevant to the decision process. This will by default include all referee comments directed to the authors, as well as the authors' point-by-point responses. Internal communications and informal consultations between editors and editorial advisors will remain excluded from these policies. Likewise, referee anonymity will be strictly maintained. Authors who are, for specific reasons or as a matter of principle, not comfortable with these disclosures will have the possibility to opt out of the transparent process at any stage prior to publication.
Authors of accepted peer-reviewed original articles may choose to pay a fee in order for their published article to be made freely accessible to all immediately upon publication. Please visit the section on Charges below.
Article Types
The EMBO Journal publishes the following article types:
Research Articles
Full-length original research papers, reporting novel findings in all molecular biology-related fields. Papers are assessed with regard to mechanistic insight, physiological relevance, and the level of conceptual advance.
Focus Issue Reviews - Series of commissioned reviews highlighting diverse aspects of a topical biological theme.
EMBO Member Reviews - Reviews contributed by newly elected EMBO Members, providing an overview of the current state and future directions of the Member's field.
Have You Seen?
Commissioned short commentaries on specific articles, discussing the advance and the broader implications of the respective study.
Policies, news and comment.
Correspondence concerning the validity of data or its interpretation in articles published in The EMBO Journal (see below for further information).
Editorial Policies
Submission of a manuscript implies that it reports unpublished work and that neither itself, nor parts of it, have been published or are under consideration for publication elsewhere. By submitting a manuscript to The EMBO Journal, the authors guarantee that they have the appropriate authority from their employers and/or funding agencies to publish the work. Any related work under consideration, review, revision or accepted for publication elsewhere must accompany the submission if they are relevant to its scientific assessment.
The EMBO Journal reserves the right not to publish material that has already been pre-published (either in electronic or other media). The EMBO Journal does allow prior publication on recognized community preprint servers (e.g. arXiv or Nature Precedings) for review by other scientists in the field before formal submission to the journal. The details of the preprint server concerned and any accession numbers must be included in the cover letter accompanying submission of the manuscript.
Authorship Guidelines
Submission of a paper implies that all authors have seen and approved the manuscript and its contents, and that they are aware of the responsibilities connected to authorship. Signatures from all the authors are not required; it is the corresponding author's responsibility to obtain agreement from all authors supporting the submission. All authors will be notified upon receipt of a new manuscript and upon acceptance of a manuscript, but the editorial office corresponds only with the Corresponding Author, whose responsibility it is to communicate with all other authors.
The nature of every author's contribution must be specified both in the manuscript submission system and in the manuscript under the heading "Author Contributions".
Our authorship policies conform to international standards (see, for example, http://www.icmje.org/ethical_1author.html).
We encourage the submission of a completed author checklist (right click to download) at submission (which covers animal welfare, human subjects, data deposition and ethics), and will require it to be filled and returned to the editorial office at revision, either via the online submission system (upload as a supplementary file) or by email (firstname.lastname@example.com).
Use of living organisms
For Research Articles submitted to The EMBO Journal reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. The manuscript must include a statement in the Materials and Methods identifying the institutional and/or licensing committee approving the experiments, including any relevant details. For experiments involving human subjects, authors must identify the committee approving the experiments, and include with their submission a statement confirming that informed consent was obtained from all subjects.
Right click to download and complete the author checklist here.
Animal welfare
For studies reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. The manuscript must include a statement in the Materials and Methods identifying the institutional and/or licensing committee approving the experiments. The editors reserve the right to consult with board members or external experts and reject manuscripts that contain animal experiments that do not conform to NIH or MRC guidelines for animal welfare. For further information see: http://grants.nih.gov/grants/olaw/olaw.htm; http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Useofanimals/index.htm.
We encourage authors to follow the ARRIVE guidelines (PLoS Biol. 8(6), e1000412, 2010) for reporting studies involving animals. Please see the following website for details: http://www.equator-network.org/reporting-guidelines/improving-bioscience-research-reporting-the-arrive-guidelines-for-reporting-animal-research/
Right click to download and complete the author checklist here.
Human Subjects
For experiments involving human subjects the corresponding author must identify the committee approving the experiments and include a statement that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Editors or referees may request further documentation confirming that this is the case.
Any restrictions on the availability or on the use of human data or samples should be clearly specified in the manuscript. Any restrictions that may detract from the overall impact of a study or undermine its reproducibility will be taken into account in the editorial decision.
For clinical trials reporting, the authors should fill out a CONSORT flow diagram and submit it as supplementary information. We also encourage authors to follow the CONSORT reporting guidelines http://www.consort-statement.org. Please see the EQUATOR website for details. Clinical trials should also be registered as recommended by the International Committee of Medical Journal Editors, and the trial registration number should be provided.
Right click to download and complete the author checklist here.
Reporting Guidelines
Authors are encouraged to follow the EQUATOR Network reporting guidelines for the following:
Type of Study | Guidelines |
Animal research | ARRIVE |
Parallel group randomized trials | CONSORT |
Conensus-based Clinical Case Reporting | CARE |
Prognostic marker studies | REMARK |
Diagnostic Accuracy | STARD |
Meta-analysis of observational studies | MOOSE |
Systematic reviews and meta-analysis | PRISMA |
Observational studies | STROBE |
Genetic association studies | STREGA |
Statistical analyses and methods | STAMPL |
Microarray/deep sequencing studies | MIAME |
Studies using biospecimens | BRISQ |
Planned research and results from experiments should be evaluated at an early stage for possible dual use concerns. In such cases, authors should first consult with an appropriate local body concerning the implications for biosecurity and public health. For further information see the U.S. National Science Advisory Board for Biosecurity's recommendations and the US National Select Agent Registry.
Authors should explicitly describe any potential biosecurity implications and the local body's assessment in their cover letter at submission and in the author checklist. The threat posed by the potential abuse of certain experimental data or material for bioweapons, terrorist or other criminal activities may require that editors balance the risks and benefits of publication. The ultimate decision whether to publish the paper as submitted or with suggested changes is the prerogative of the editors after consultation with board members or external experts in biosafety, biosecurity, or public and environmental health.
Right click to download and complete the author checklist here.
Availability of published material and data
It is understood that by publishing a paper in The EMBO Journal the authors agree to make available to colleagues in academic research all new reagents, including organisms (or means to produce them), viruses, cells, nucleic acids and antibodies, that were used in the research reported and that are not available from public repositories or commercial suppliers. Human patient samples and data should be made available in accordance with the relevant ethical standards. Materials must be made available at a reasonable cost that reflects production and distribution. The distribution of published materials does not automatically confer a right of co-authorship. Right click to download and complete the author checklist here.
The EMBO Journal will only review and publish manuscripts if the authors agree to make all data that cannot be published in the journal itself (e.g. novel nucleotide sequences, structural data, or data from large-scale gene expression experiments) freely available, where possible in an appropriate public database (detailed guidelines can be found below).
Right click to download and complete the author checklist here.
Conflicts of interest
In the interests of transparency and to help editors and reviewers assess any potential bias, The EMBO Journal requires authors of original research papers to declare any competing commercial interests in relation to the submitted work. It is difficult to specify a threshold at which a financial interest becomes significant, but as a practical guideline, we would suggest this to be any undeclared interest that could embarrass you were it to become publicly known. Referees and editors are also subject to Conflict of Interest regulations.
Scientific Integrity
The editorial staff of The EMBO Journal is strongly committed to maintaining high standards of integrity of the published scientific record. The journal requests that authors take note of and adhere to guidelines established by the U.S. Department of Health and Human Services Office of Research Integrity (http://ori.dhhs.gov). The journal will investigate suspected instances of scientific fraud, inappropriate image manipulation, plagiarism, duplicate publication and other cases that violate research ethics. Depending on the outcome of these investigations, the journal may opt to publish errata or corrigenda, or, in cases of serious scientific misconduct, either to ask authors to retract their paper, or to impose retraction on them. In such cases, the authors' employers may also be contacted. As a matter of policy, the journal will collaborate with independent institutional investigations into misconduct and usually accept the outcome of such investigations.
An erratum is notification of an important error made by the journal, whereas a corrigendum is notification of an important error made by the author(s).
Refutations of articles published in The EMBO Journal can be considered for the Correspondence section of the journal. Such correspondence will almost always include data to support the arguments of the correspondent. The original authors of that article will be offered the opportunity to respond side-by-side with the correspondence. Both pieces will be peer reviewed at the discretion of the editor and acceptance depends on the strength of the arguments raised as well as the importance of the matter to a general readership. Publication of the correspondence does not automatically entail publication of a response of the authors of the challenged research paper. After one round of correspondence, The EMBO Journal will consider the matter closed and will not publish further exchanges.
The EMBO Journal is a member of the Committee on Publication Ethics (COPE).
Data collection and presentation
Presented data must represent the findings in a fair and accurate manner. This includes appropriate statistical analysis and image processing. For further details, please refer to these guidelines.
The Editors reserve the right to request original versions of figures and the source data that were used to assemble the figure from the authors of a paper under consideration, or of a paper already published in The EMBO Journal.
Originality and Plagiarism
The editors require that any information published in the journal represents a substantially novel contribution to the scientific record. Any manuscript submitted to The EMBO Journal should therefore not contain content that has been formally published in a peer reviewed journal or another formally citable manner, whether in print or electronic. This includes websites, blogs and the news media.
Embargo Policy
The content of papers and any associated press releases is strictly embargoed until the official date of publication of a manuscript. Accepted contributions can be discussed with the media from one week before the publication date provided the journalist respects the embargo date. We will press release selected papers with summaries. Authors may arrange their own publicity, but must adhere to the embargo conditions. Further details can be provided by the editorial office (email@example.com).
Comprehensive and accurate citation of the relevant literature is essential. We require citation of the primary literature wherever appropriate. To enable this, we have removed any limits on the total number of references in the bibliography, and the reference list is no longer subject to manuscript length format requirements (for details, see below). Similarly, page charges will apply only to the body of a published article, not to the reference list.
Editorial Process
All submissions are initially assessed by a dedicated in-house editor specialised in the scientific topics covered in the manuscript, and may also be evaluated by an appropriate Editorial Advisory Board member, or other external expert advisor. Only manuscripts judged by the editors to be potentially suitable for publication in The EMBO Journal are sent out for formal peer review, so that manuscripts with a low probability of success can be returned to the authors without delay. Manuscripts are generally reviewed by three appropriate experts selected by the editors. Based on their arguments and recommendations, the decision concerning publication, revision or rejection is taken, sometimes after further consultation with the referees, the editorial advisory board or indeed the authors. Revisions are invited only for manuscripts that have a high probability of acceptance after one major round of revision. Authors may appeal decisions if there is concrete evidence for a misunderstanding or mistake at the editorial or referee level. Appeals are evaluated in depth and without prejudice.
The EMBO Journal makes the editorial process transparent for all accepted manuscripts, by publishing as an online supplementary document (the Peer Review Process File, PRPF) all correspondence between authors and the editorial office relevant to the decision process. This will include all referee comments directed to the authors, as well as the authors' point-by-point responses. Internal communications and informal consultations between editors, editorial advisors or referees will remain excluded from these documents. Importantly, referee anonymity will be strictly maintained. Authors have the possibility to opt out of the transparent process at any stage prior to publication.
To further facilitate transparency, The EMBO Journal has removed the "Confidential Comments" field from our referee reporting forms. This is to ensure that the authors receive all information pertinent to the decision made on a manuscript. Referees should be aware that all comments will be transmitted to the authors and the other referees. Should there be any issues with the manuscript, in particular concerns about ethical standards, data integrity, biosecurity, or conflicts of an academic or commercial nature that need to be communicated directly and confidentially to the editor, this can be done by email (firstname.lastname@example.com).
Please see the following editorials for more information on these policies.
The EMBO Journal 2009: New Initiatives
A Transparent Black Box
Transfer policies
The EMBO Journal is editorially independent of its publishers and of the other EMBO Scientific Publications.
Authors can choose to transfer manuscripts rejected from The EMBO Journal to any of the other three EMBO Publications (EMBO reports, Molecular Systems Biology, EMBO Molecular Medicine) by following the instructions appended to the editorial decision letter. Manuscripts transferred post-review will automatically include the referees' reports and identities, and the editors will aim to use these reports in arriving at a rapid decision. Editors may choose to seek additional advice from referees or editorial advisory board members in cases where this would enhance informed decision-making.
Manuscript Preparation
General Guidelines for Submission
The following guidelines refer to Research Articles, although many also apply to other, commissioned, article types. The Editors reserve the right to return manuscripts that are not in accordance with the following instructions. However, manuscript will not be rejected out of hand for format reasons: while published manuscripts are expected to conform tightly to the following guidelines, this is not a requirement at first submission.
Manuscripts must be written in clear and concise English and be intelligible to a broad readership. Prior to submission, authors may benefit from having their manuscript reviewed for clarity by colleagues and/or by using one of the many English language-editing services that are available.
Manuscripts for primary research articles should be around 55,000 characters - excluding the references - and can contain around 9 figures. These are not strictly enforced limits.
Manuscript Format
Submitted manuscripts should be divided into the following sections:
- Title page
- Abstract
- Introduction
- Results
- Discussion
- Materials and methods
- Acknowledgements
- Author Contributions
- Conflict of Interest
- References
- Figure legends
- Figures
- Tables
- Expanded View (replaces Supplementary Information)
Title Page
The title should be short and informative, and should not contain any abbreviations (for example, Epithelial-Mesenchymal Transition should not be abbreviated to EMT). However, commonly used gene or protein acronyms are acceptable. The total length of the title should not exceed 100 characters (including spaces). Serial titles are not accepted.
The full name of each author should be given. Multiple first-authorships are acceptable and should be indicated. Numbers in superscript should be used to indicate the department, institution, city with postal code and country, for each author. Any changes of address may also be given in numbered footnotes. It is possible to name more than one author as the correspondent of a published article, although we will by default address all correspondence to the single author listed as Corresponding Author upon submission.
Please provide a running title of no more than 50 characters including spaces.
Up to five keywords, which may or may not appear in the title, should be given in alphabetical order, below the abstract, each separated by a slash (/).
This should be a single paragraph not exceeding 175 words. The Abstract should be comprehensible to readers before they have read the paper, and abbreviations should be avoided where possible (as for the title). Reference citations within the abstract are not permitted. The abstract should describe all key novel findings of the study.
The Introduction should be succinct and without subheadings. It should provide only the necessary background information, rather than comprise a comprehensive review of the field. Citation of the primary literature is required where appropriate (see section on Citations).
The Results section, and associated figures, tables and Expanded View information, must accurately describe the findings of the study. Figure order should follow the text. Detailed methodological descriptions should be restricted to the Materials and Methods section. 'Data not shown' is not permitted (see below): all significant data should be displayed in the main figures or Expanded View information.
The Discussion should accurately interpret the results, but not be repetitive with the Results section. Authors are encouraged to discuss their work in the broader context. Related published data must be appropriately discussed and cited. Speculation is allowed but should be clearly labelled as such.
Materials and methods
This section should contain sufficient detail so that all experimental procedures can be repeated by others, in conjunction with cited references. Reagents must be described in such a way as to allow readers to identify them unequivocally and/or reproduce them. For example, antibodies epitopes should be described and siRNA and other probe sequences must be provided. In cases where detailed methods cannot be described within the length limits of the article, additional Materials and Methods can be included as part of the Expanded View. This additional information should, however, not be of immediate importance for the understanding of the manuscript, and it is not permissible to move the entire "Materials and methods" section into the online supplement.
These should be placed at the end of the text and not in footnotes. Personal acknowledgements should precede those of institutions or agencies. Grant numbers are permissible. Dedications are discouraged.
Author Contribution
The EMBO Journal requires a statement specifying the contributions of every author. Further details on authorship can be found here.
Conflict of Interest
The EMBO Journal requires a statement specifying whether or not the authors have a Conflict of Interest (see above for details). In the case of a Conflict of Interest, this must be specified.
As a matter of policy, The EMBO Journal requires the citation of primary literature (over review articles) wherever appropriate. Authors are responsible for the accuracy of the references. Authors are responsible for ensuring that the related literature is accurately and comprehensively discussed and cited. Review articles should only be cited for general background information, the proposal of certain concepts or similar purposes, whereas primary research articles should preferentially be referenced to introduce the question being addressed or to support the conclusions and interpretations of the results. Articles in press can be cited with the explicit permission corresponding author of the study; the journal name has to be included and, where available, the Digital Object Identifier. Reference formatting information can be found here.
Figure Legends
Figure legends should contain sufficient information to allow the reader to follow the data presented without referring back to the text, but should not be redundant with the Results section. Each figure must contain a heading, and each panel a subheading. All symbols and abbreviations used in the figure must be defined, unless they are common abbreviations or have already been defined in the text. Experimental details should, where possible, be given in the Materials and Methods section, and not repeated in the figure legends. Figure legends should be formatted such that each panel, or group of panels, has its own entry with the panel letter (or range) on the left and the description on the right. The description of specific panels can be preceded or followed by free text describing features, statistics or values pertinent to all panels. For example:
Figure 1 - Generation of hiPSCs from a patient with type-2 long-QT syndrome.
A Genetic screening in the patient revealed the heterozygous single-nucleotide mutation Aright arrowT in exon 13 of the KCNH2 gene, in position 2987 of the coding sequence (CDS) (c.A2987T, NM_000238.3), resulting in the substitution of an asparagine with an isoleucine at position 996 of the protein (N996I, NP_000229.1).
B The N996I mutation (red dot) is located in the C-terminal of the HERG protein, which is made of six trans-membrane domains (S1-S6), an amino (NH2) domain, a carboxyl (COOH) domain, and a pore (P) region.
C Example of a hiPSC colony harbouring the c.A2987T (N996I) KCNH2 mutation (LQT2-hiPSCsN996I). Scale bar: 400 mu;m.
D Immunofluorescence analysis of pluripotency markers SSEA4 (green) and NANOG (red) in a representative LQT2-hiPSCN996I clone, with nuclear staining (DNA, blue). The image on the right is a magnification of the area framed in the left image. Scale bars: 100 mu;m (left image); 50 mu;m (right image).
Expanded View (replacing Supplementary Information)
[Note: authors do NOT need to reformat their manuscript at first submission. The guidelines below are to be followed when submitting a revision.]
All data and information that are essential to support the scientific arguments made in the paper should be presented in figures that will be included in the main paper. Figures, tables or text sections that are not required by the general reader to understand the principle findings of the paper and that would disrupt the flow of paper should be submitted as 'Expanded View', which will be displayed in collapsible form and will replace Supplementary Information.
The printed article must be complete and self-explanatory without the Expanded View content. Please refer to each Expanded View item in the body of the text or the figure legends. You should also include the text "Expanded View information is available at The EMBO Journal Online' at the end of the article and before the references.
Expanded View Figures, tables or text represent an integral part of the published paper and benefit from the same peer-review and editorial production process as the other sections of the paper. Please note the Expanded View items are restricted to information essential to support the scientific arguments made in the paper. Peripheral, tangential or further reaching data and information should not be presented. Reference to 'data not shown' is discouraged'.
Expanded View items (Figures, Tables, Text) are displayed inline in the HTML version of the paper and are individually expandable/collapsible [note: currently files are linked to for download but full HTML rendering will come in the near future].
The article should be self-explanatory without the Expanded View sections. The scope of Expanded View sections should therefore be limited to the following categories:
- controls and results from technical optimization experiments
- replication or confirmation of previous results
- negative results
- extended methods and detailed protocols
- mathematical demonstrations, algorithms, computer code and models
- datasets
Note that controls and replicates to directly support the data presented in a figure should be supplied as 'Source Data' file linked to the relevant figure.
All Expanded View items should be cited in the text as "Figure E1", "Figure E2", Table E1", "Table E2", etc..., throughout the text.
Every Expanded View item should be accompanied by a legend that explains the content of the item. Expanded View legends should simply be included in the main manuscript file after the legends to the Figures and use the conventional format:
- "Figure E1. Title of the item. Explanatory legend."
Each Expanded View item should in principle be supplied as an individual file. If this is not possible due to the nature of the information provided in Expanded View and the way it needs to be presented, a single PDF file (including a Table of Contents) can also be provided in exceptional cases and in agreement with the editors.
The following formats are accepted:
- Expanded View Figure: jpg, gif, tiff, eps, pdf
- Expanded View Tables (less than 50 rows): Word, Excel
- Expanded View Text: Word, LaTeX
- Expanded View Datasets and large tables (more than 50 rows): Excel, tab-delimited text, comma-separated values (csv), XML
- Expanded View Code and Models: plain text, XML, ZIP compressed archives (including a README text file at the top level to detail the content and nature of each file included in the archive)
- Expanded View Movie: mpeg, mov, avi
For the PDF version of the article, all displayable Expanded View items (Figures, Text and small tables) are automatically converted into PDF format and appended to the end of the article as part of a single downloadable 'PDF+' file. Files marked 'PDF' display the paper without Expandable View Items.
Unpublished Data
The EMBO Journal does not permit citation of "Data not shown". All data referred to in the paper should be displayed in the main or Expanded View figures. "Unpublished observations" may be referred to in exceptional cases, where these are data peripheral to the major message of the paper and are intended to form part of a future or separate study. Personal communications (Author name(s), personal communications) must be authorised in writing by those involved, and the authorisation sent to the editorial office at time of submission. Care should be taken that embargo policies are not contravened. References to manuscripts in preparation or submitted, but not yet accepted, should be cited in the text as (Author names(s), in preparation), and should not be included in the list of references. Copies of such manuscripts should be enclosed at submission for reviewing purposes where relevant, as should manuscripts in press, which should be cited in the reference list (see below)
Conventions and Abbreviations
In general, the journal follows conventions given in Scientific Style and Format: The CBE Manual for Authors, Editors and Publishers (1994) Cambridge University Press, Cambridge, UK, 6th edn. Please follow Chemical Abstracts and its indexes for chemical names. For guidance in the use of biochemical terminology follow the recommendations issued by the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature. In general, genes and genotypes should be indicated in italics; proteins and phenotypes should not be italicized.
Authors should use approved gene and gene product nomenclature and apply the italicization and capitalization formatting as appropriate for each organism's standard nomenclature. Please consult the appropriate nomenclature databases for correct gene names and symbols. Some useful general resources are: Entrez Gene (http://www.ncbi.nlm.nih.gov/gene); UniProt (http://www.uniprot.org/).
Try to restrict the use of abbreviations to SI symbols (standard units of measurements) and those recommended by the International Union of Pure and Applied Chemistry (IUPAC). Abbreviations should be defined in brackets after their first mention in the text, not in a list of abbreviations. SI symbols and symbols of chemical elements may be used without definition in the body of the paper. Abbreviations of standard biochemical compounds, e.g. ATP, DNA, nucleotides in nucleic acids, and amino acids in proteins, need not be defined. Common language abbreviations, such as e.g. or i.e., should not be used.
General Formatting Guidelines
The Editorial Office will only accept text files in RTF or MS Word format. The final character count must be clearly indicated on the title page of the manuscript. Manuscripts that do not comply with the formatting guidelines, or exceed the length restrictions, may be returned to the authors for amendment.
Please submit the full text (including figure legends, tables, and references) as a single MS Word or RTF file.
Figures and Expanded View figures should be presented in the order they are mentioned in the text.
Figures should be labelled in consecutive Arabic numerals. The final size of figures will be between 82 mm and 172 mm wide on the printed page. Please bear this in mind when submitting your manuscript for review and allow for sufficient resolution at a suitable size.
Figures divided into parts should be labelled with an upper-case, bold letter (Helvetica Font). Figures with several parts should also be in proportion, with consistently sized lettering so that the whole figure can be reduced by the same amount to the smallest size at which the essential details are visible. Use Courier font for sequence data and Symbol font for any symbols.
All lettering should be done using standard fonts (Helvetica, Times, Symbol, Courier) and retained in a separate layer (if possible) so that the production team can adapt any labels to the Journal's style if necessary. All fonts used for labelling the figures should also be embedded in the final files if the software package offers this option.
Scale bars, rather than magnification factors, should be used, with the length of the bar defined in the legend rather than on the bar itself. In general, visual cues on the figure itself are preferred rather than verbal explanations (for example, 'broken line' or 'filled black triangles') in the legend.
When preparing figures of microscopy images, please note that we strongly encourage the use of colours that are suitable for colour-blind readers: for example, the use of magenta/green is preferred over red/green for 2-channel images.
For publication, we use TIFF and EPS files in PC or Macintosh format, preferably from PhotoShop or Illustrator software. We cannot accept Freehand, Canvas, CorelDRAW or MacDrawPro files. These files must be converted to postscript (eps) format. For any figures submitted in photoshop or tiff format we require layered files to be sent whereby all text, arrows or additional attributes are placed on individual layers within the file. For line art/charts/graphs we prefer to work with Adobe Illustrator AI or EPS files. We can also accept high-resolution PDF files.
All colour artwork must be submitted in CMYK colour mode. When converting files from RGB, please consider that the final figures will be printed on coated paper, using Euroscale process inks. If you are not familiar with these specifications, or are not sure how to apply them within your software package, please consult a local graphics expert. Ultimately, it is important that all colours look satisfactory after conversion to CMYK, both on screen and when printed on different printers.
Non-vector graphics should be preserved at high resolution: 300 dpi minimum at final size for greyscale or colour halftone images, and 1,000 dpi minimum for bitmap (b/w) artwork.
Further detailed guidelines regarding the preparation of artwork is available to download in this document [pdf].
The EMBO Journal does not have colour charges for figures, and the authors are therefore welcome to submit full colour figures. Details on page charges can be found in the Charges section below.
Data presentation
Figures must accurately reflect the results of the experiments. Appropriate controls, markers and scale bars should be included in all panels. Statistical tests must be clearly defined and appropriate to the data.
Image Processing
Images submitted with a manuscript for review should be minimally processed (for instance, to add arrows to a micrograph). Authors should retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data are unavailable, manuscript evaluation may be stalled until the issue is resolved. All digitized images submitted with the final revision of the manuscript must be of high quality and have resolutions of at least 300 d.p.i. for colour, 600 d.p.i. for greyscale and 1,200 d.p.i. for line art.
A certain degree of image processing is acceptable for publication (and for some experiments, fields and techniques is unavoidable), but the final image must correctly represent the original data and conform to community standards. The guidelines below will aid in accurate data presentation at the image processing level; authors must also take care to exercise prudence during data acquisition, where misrepresentation must equally be avoided. Where appropriate, manuscripts should include further Methods as part of the Expanded View that describe for each figure the pertinent instrument settings, acquisition conditions and processing changes, as described in this guide.
Authors should list all image acquisition tools and image processing software packages used. Authors should document key image-gathering settings and processing manipulations in the Methods.
Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. If juxtaposing images is essential, the borders should be clearly demarcated in the figure and described in the legend.
The use of touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, is to be avoided.
Processing (such as changing brightness and contrast) is appropriate only when it is applied equally across the entire image and is applied equally to controls. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (for example, through the use of a biased choice of threshold settings), is inappropriate, as is emphasizing experimental data relative to the control.
When submitting revised final figures upon conditional acceptance, authors may be asked to submit original, unprocessed images.
Electrophoretic gels and blots
Positive and negative controls, as well as molecular size markers, should be included on each gel and blot. For previously characterized antibodies, a citation must be provided. For antibodies less well characterized in the system under study, a detailed characterization that demonstrates not only the specificity of the antibody, but also the range of reactivity of the reagent in the assay, should be published as part of the Expanded View. The display of cropped gels and blots in the main paper is permitted if it improves the clarity and conciseness of the presentation. Cropped gels in the paper must retain all important bands, and space (several band-widths) should be retained above and below the relevant band(s). Vertically sliced images that juxtapose lanes that were non-adjacent in the gel must have a clear separation or a black line delineating the boundary between the gels. Quantitative comparisons between samples on different gels/blots are discouraged; if this is unavoidable, the figure legend must state that the samples derive from the same experiment and that gels/blots were processed in parallel. Loading controls must be run on the same blot. High-contrast gels and blots are discouraged, as overexposure may mask additional bands. Authors should strive for exposures with gray backgrounds. Multiple exposures should be presented in the Expanded View information if high contrast is unavoidable. Immunoblots should be surrounded by a black line to indicate the borders of the blot, if the background is faint. For quantitative comparisons, appropriate reagents, controls and imaging methods with linear signal ranges should be used.
Authors should be prepared to supply the editors with original data on request, at the resolution collected, from which their images were generated. Cells from multiple fields should not be juxtaposed in a single field; instead multiple supporting fields of cells should be shown as part of the Expanded View. Specific guidelines: Adjustments should be applied to the entire image. Threshold manipulation, expansion or contraction of signal ranges and the altering of high signals should be avoided. If 'Pseudo-colouring' and nonlinear adjustment (for example 'gamma changes') are used, this must be disclosed. Adjustments of individual colour channels are sometimes necessary on 'merged' images, but this should be noted in the figure legend. We encourage inclusion of the following with the final revised version of the manuscript for publication: In the Methods, specify the type of equipment (microscopes/objective lenses, cameras, detectors, filter model and batch number) and acquisition software used. Although we appreciate that there is some variation between instruments, equipment settings for critical measurements should also be listed. A further Methods section as part of the Expanded View (or part of a larger Methods section) titled 'equipment and settings' should list for each image: acquisition information, including time and space resolution data (xyzt and pixel dimensions); image bit depth; experimental conditions such as temperature and imaging medium; and fluorochromes (excitation and emission wavelengths or ranges, filters, dichroic beamsplitters, if any). The display lookup table (LUT) and the quantitative map between the LUT and the bitmap should be provided, especially when rainbow pseudocolor is used. If the LUT is linear and covers the full range of the data, that should be stated. Processing software should be named and manipulations indicated (such as type of deconvolution, three-dimensional reconstructions, surface and volume rendering, 'gamma changes', filtering, thresholding and projection). Authors should state the measured resolution at which an image was acquired and any downstream processing or averaging that enhances the resolution of the image.
Statistical analysis
The description of all reported data that includes statistical testing must state the name of the statistical test used to generate error bars and P values, the number (n) of independent experiments underlying each data point (not replicate measures of one sample), and the actual P value for each test (not merely 'significant' or 'P < 0.05'). Descriptive statistics should include a clearly labelled measure of centre (such as the mean or the median), and a clearly labelled measure of variability (such as standard deviation or range). Ranges are more appropriate than standard deviations or standard errors for small data sets. Standard error or confidence interval is appropriate to compare data to a control. Graphs must include clearly labelled error bars for cases where more than two independent experiments have been performed (error bars for replicate samples are less useful). Authors must state whether a number that follows the ± sign is a standard error (s.e.m.) or a standard deviation (s.d.) Figure legends should contain a basic description of n, P and the test applied, and the Methods should contain further discussion of statistical methodology. Since for complex biological experiments the number of independent repeats of a measurement often has to be limited for practical reasons, statistical measures with a very small n are commonplace. However, statistical measures applied to too small a sample size are not significant and they can suggest a false level of significance. We recommend that the actual individual data from each experiment should be plotted if n < 5, alongside an error bar. In cases where n is small, a justification for the use of the statistical test employed has to be provided. Presenting a single 'typical result' of n experiments is sometimes unavoidable, but should be accompanied by an indication of the variability of data between independent experiments. If n is not based on independent experiments (that is, n merely represents replicates of a measurement), statistics may still be useful, but a detailed description of the repeated measurement is required.
Authors must justify the use of a particular test and explain whether their data conform to the assumptions of the tests.
Tables should be typed on separate sheets and numbered consecutively with Roman numerals (I, II, III, IV,). Tables should be self-explanatory and include a brief descriptive title. Footnotes to tables indicated by lower-case superscript letters are acceptable, but they should not include extensive experimental detail.
Only articles that have been published or that are accepted for publication at a named publication should be cited in the reference list. In the text of the manuscript, a reference should be cited by author and year of publication; no more than two authors may be cited per reference; 'et al' should be used if there are more than two authors (i.e. Smith & Jones, 2003; Smith et al, 2000). Papers accepted for publication must be cited with the corresponding author's permission and should include title and all author names (or initials if any of the authors are co-authors of the present contribution), as well as either the DOI, if available, or the term 'in press'. In the reference list, citations should be listed in alphabetical order and then chronologically, with the authors' surnames and initials inverted; where there are more than 20 authors on a paper, the first 20 will be listed, followed by 'et al.'. Publications by the same author(s) in the same year should be identified with a, b, c after the year of publication. The name of each journal should be abbreviated according to Index Medicus and italicized. References should therefore be listed (and will subsequently appear in print) as follows:
Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE (2002) Aspirin and lung cancer in women. Br J Cancer 87: 49-53
Book chapters and books can be cited in the following way:
Price SR, Oubridge C, Varani G, Nagai K (1998) Preparation of RNA-protein complexes for X-ray crystallography and NMR. In RNA-Protein Interaction: Practical Approach, Smith C (ed) pp 37-74. Oxford: Oxford University Press
Sambrook J, Fritsch E & Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Press, Cold Spring Harbour, New York, USA
Links to online resources and websites should be cited in the text only, and should be available long-term (e.g. permalinks or DOI wherever possible). URLs should not appear in the reference list.
Data deposition
Large-scale datasets, sequences, atomic coordinates and computational models should be deposited in one of the relevant public databases prior to submission (provided private access is available at the database) and authors should include accession codes in the Materials & Methods section. The suggested wording for referring to accession identifiers in a manuscript is the following: "The [protein interaction | microarray | mass spectrometry ] data from this publication have been submitted to the [name of the database] database [URL] and assigned the identifier [accession | permalink | hashtag ]." If necessary, please include in the manuscript the relevant information (username and password) for confidential access by peer-reviewers.
Data for which no suitable public database exists should be included, if possible, as dataset files in the Expanded View. In cases where data can not be confidentially deposited in a public database, and is too large to be included in the Expanded View, please contact the editorial office for advice on how to make these data available for refereeing purposes.
Functional genomics data
Microarray and sequencing-based functional genomics data should be deposited in the ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), GEO (http://www.ncbi.nlm.nih.gov/geo/) or CIBEX (http://cibex.nig.ac.jp/index.jsp) databases in compliance to the MIAME (http://www.mged.org/Workgroups/MIAME/miame.html) standards and the MINSEQE (http://www.mged.org/minseqe/) draft proposal.
Proteomics, metabolomics and molecular interactions
Mass spectrometry datasets should be deposited in a machine-readable format (e.g. mzML if possible) in one of the major public database, for example Pride (http://www.ebi.ac.uk/pride/) or PeptideAtlas (http://www.peptideatlas.org) and authors should follow the MIAPE recommendations (http://www.psidev.info/index.php?q=node/91).
Molecular interaction data should be deposited with a member of the International Molecular Exchange Consortium (IMEx, http://www.imexconsortium.org) prior to submission of the manuscript. Authors should follow the MIMIx recommendations (http://www.psidev.info/index.php?q=node/278).
Metabolomics data should be deposited following the recommendations of the Metabolomics Standards Initiative (MSI) (http://metabolomicssociety.org/index.php/resources/metabolomics-standards) in a recognised repository such as MetaboLights (http://www.ebi.ac.uk/metabolights/).
Sequence data
Nucleotide sequence data should be submitted to an International Nucleotide Sequence Database Collaboration member: GenBank (http://www.ncbi.nlm.nih.gov/genbank/), EMBL Nucleotide Sequence Database (http://www.ebi.ac.uk/embl/) or DDBJ (http://www.ddbj.nig.ac.jp/).
Structural data
The EMBO Journal accepts and follows the recommendations of the International Union of Crystallography (IUCr), with regard to the deposition and release of macromolecular structural data. These guidelines are set out in the article by the IUCr Commission on Biological Macromolecules in Acta Crystallographica (2000), D56, 2. In summary, they state that all publications must be accompanied by deposition of both the atomic coordinates and the structure-factor amplitudes in the appropriate database (PDB or NDB). In the case of low-resolution structures for which only a chain trace is reported, a set of C alpha positions and structure-factor amplitudes may be sufficient.
For NMR structures, data deposited should include resonance assignments, and all restraints used in structure determination (NOEs, spin-spin coupling constants, amide exchange rates, etc) and the derived atomic coordinates for both an individual structure and for a family of acceptable structures.
Structures of biological macromolecules solved by electron microscopy must be submitted to the EMDB database at http://emdatabank.org. For a brief description of the database, see Lawson et al. (2011) Nucleic Acids Res. 39: D456-D464.
Human clinical and genomic datasets
The EMBO Journal encourages authors to provide access to genotype and clinical data with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-controlled repositories such as dbGAP (http://www.ncbi.nlm.nih.gov/gap) or EGA (http://www.ebi.ac.uk/ega). Simple genetic polymorphisms should be submitted to dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).
Right click to download and complete the author checklist here.
Presubmission Enquiries
Presubmission enquires allow authors to receive rapid feedback on whether a manuscript in preparation is likely to be of interest to the journal. Presubmission enquiries should be submitted via our online submission system (http://emboj.msubmit.net) or by e-mail (email@example.com) and should minimally include a list of all authors, a cover letter and an abstract.
If you have already prepared a manuscript, please submit this via our online system as an article, rather than sending a presubmission enquiry. This allows the editors to make a more informed decision as to whether or not the manuscript is potentially appropriate for the journal. Initial editorial assessment of full submissions at The EMBO Journal is usually rapid, with an average decision time of four days (details of our handling statistics can be found here).
How to Submit
We use an online manuscript submission and tracking system: http://emboj.msubmit.net
In order to submit, you must have registered for an account. After this, please consult the following instrutions for submission via our secure server. Please be sure that your browser is set to accept cookies. Our tracking system requires cookies for proper operation.
Please refrain from submitting your manuscript by e-mail attachment.
For original submissions, you will need to upload a cover letter, a Word file of the text of the manuscript (including figure legends), and a PDF file containing all the figures. Alternatively, individual figure files can be uploaded separately but please note that this can be more time-consuming than a PDF submission. Additional Expanded View files can also be uploaded when applicable (please refer to the section 'Expanded View' above).
Once you have submitted your files and the conversion is in progress, it can take up to 30 minutes before the PDF, created in the conversion process, is ready for approval. Please contact the editorial office [email@example.com] if the conversion engine takes longer than this. It is important to check the quality of the figures in the converted PDF before approving the submission. Please remember that your manuscript will not be submitted until you have approved the converted files.
To avoid any unnecessary delays, please refer to the most current electronic formatting guidelines when preparing your manuscript for submission. Authors using computer systems with non-Western type encoding are strongly encouraged to eliminate all occurrences of non-standard fonts in both the manuscript and the figures. We suggest using only the fonts Times, Symbol, Courier and Helvetica.
We will acknowledge receipt of a submitted manuscript by e-mail as soon as the quality check (appropriate manuscript format and image quality) has been completed. All further correspondence will also be by e-mail. Please ensure that your servers are set up to allow e-mails from the journal, and contact us if you do not receive an acknowledgement e-mail within a few days of submission.
Manuscript Status
You can check the status of your manuscript at any time in the review process by:
- Accessing the system with your password or link sent to you in the acknowledgement e-mail.
- Clicking on the link represented by your manuscript tracking number and abbreviated title.
- Clicking on the "Check Status" link at the bottom of the displayed page.
This procedure will display tracking information about where your manuscript is in the submission/peer review process.
Please feel free to contact the editorial office [email@example.com] with status queries.
Submission of Revisions
When a manuscript is returned to authors for revision, the revised version should be submitted within three months of the authors' receipt of the referee reports, unless another date is specified in the decision letter. Please contact the editor by the deadline in cases where extra time is required for revision. Additional time may be granted upon request at the Editors' discretion, assuming the conceptual advance of the study stands (with regard to the current literature). As a matter of policy, we do not consider any competing manuscripts published during the specified revision period as negatively impacting on the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Only a single round of revision is generally permitted. The initial decision letter on the original version of the manuscript provides a URL that should be used for submission of revised manuscripts. Please do not upload revisions as new submissions.
Revisions should be accompanied by a point-by-point response to the referees' comments as well as the editorial decision letter, in PDF or Word format. To facilitate the re-evaluation, we encourage authors to intercalate their response with the referee comments.
Revisions must also be accompanied by a completed author checklist. Right click to download and complete the author checklist here.
For Acceptance and Publication
Before acceptance and transfer to our publishers, manuscripts will be checked for appropriate formatting and image processing, and for plagiarism. We cannot proceed to acceptance until data are available in public databases when required; see above for details.
Speed of publication
The journal aims for rapid publication of papers, using Advance Online Publication of every paper to expedite the process. Please help the Editors and publisher avoid delays by providing current e-mail address(es), telephone and fax numbers at which author(s) can be contacted.
Authors will be sent an e-mail with a link to download their proof. It is the authors' responsibility to check that the final proof is accurate. In the interests of speed, corrections should be returned within 24 hours. Essential changes of an extensive nature may be made only by insertion of a 'Note added in proof', and only with the approval of the Editors. A charge will be made to authors who insist on extensive amendment within the text at the page proof stage. Excessive alterations may delay publication of the article.
Press Embargo
When discussing unpublished data (including data in accepted papers not yet published) with the press, authors should take care not to break the journal embargo policy (see above for details)
The pricing structure for The EMBO Journal for page and colour charges has been consolidated into a single processing fee called Page Charge, applicable for all articles submitted on or after 1st March 2011. This covers some of the costs of processing and producing the article for online and print publication. After final layout for publication, each page of an article will occur a fixed charge of 185 EUROS (other currencies are accepted). There are no additional charges for colour, and - in line with our citation policies - we will not charge for reference only pages.
It should be noted that the new page charges generate a similar income to the previous charges (page and colour printing) combined, and that these charges had not changed for five years.
20% VAT will be added to the total page charge amount upon invoicing. This also applies to all EU authors who do not provide a valid VAT number upon returning this form.
Please note that if EMBO OPEN is chosen, in addition to the page charges an Article Processing Charge of $3,900 will apply.
Open Access & Self Archiving
Authors of original research articles are encouraged to submit the author's version of the accepted paper (the unedited manuscript) to their funding body's archive, for public release six months after publication. In addition, authors are encouraged to archive this version of the manuscript in their institution's repositories and on their personal websites, also six months after the original publication. This is in line with EMBO Press' self-archiving policy.
Authors of research articles can also opt to pay an article processing charge of $3,900 (+VAT where applicable) for their accepted articles to be open access online immediately upon publication. By paying this charge authors are also permitted to post the final, published PDF of their article on a website, institutional repository or other free public server, immediately on publication.
Please note that EMBO OPEN charges will have to be levied in addition to the page charges, in order to cover some of the costs associated with the production process for a paper.
EMBO Press' publishing policies ensure that authors can fully comply with the public access requirements of the major funding bodies worldwide - please see www.sherpa.ac.uk for more information. However, it is the author's responsibility to take the necessary actions to achieve compliance. These may include self archiving, opting into EMBO Press' manuscript deposition service and / or choosing open access publication.
Author licence agreement
The corresponding author must complete and sign the Licence to Publish form upon acceptance of the manuscript. Failure to do so will result in delays to the publication of your paper. The corresponding author will receive instructions in the decision letter sent from the journal. Signing the license will involve following a link to the Wiley Online Author Serivces system.
EMBO Press does not require authors of original research papers to assign release copyright of their published contributions. Authors grant EMBO Press and its publishers an exclusive licence to publish, in return for which they can re-use their papers in their future printed work. Authors are encouraged to submit their version of the accepted, peer-reviewed manuscript to their funding body's archive, for public release six months after publication. In addition, authors are encouraged to archive their version of the manuscript in their institution's repositories (as well as on their personal websites), also six months after the original publication. Authors should cite the publication reference and DOI number on any deposited version, and provide a link from it to the published article. This policy is consistent with the policies of the US National Institutes of Health, the Wellcome Trust and other research funding bodies around the world. EMBO Press and its publishers recognise the efforts of funding bodies to increase access of the research they fund, and strongly encourage authors to participate in such efforts. Upon submission, authors of original research articles can opt for EMBO Press and its publishers to deposit their author accepted paper on PMC and UKPMC via the manuscript deposition service automatically after six months.
After 12 months all articles in The EMBO Journal will be converted to open access on PubMedCentral in their final published form.
EMBO Open articles are published under one of three Creative Commons licences at the free choice of the authors. The publication charges remain the same irrespective of the licence chosen.
Under the Creative Commons Attribution 3.0 Unported Licence (CC BY), users are free to share (copy, distribute and transmit) and to adapt (edit, rewrite or remix) the contribution including for commercial purposes, but with formal attribution. Users must attribute the contribution in the manner specified by the author or licensor (but not in any way that suggests that they or their use of the contribution is endorsed by the author or licensor). (see full legal code at http://creativecommons.org/licenses/by/3.0/)
The use of the CC-BY licence is mandatory for open access publication by recipients of funding from Research Councils UK (RCUK) and the Wellcome Trust after April 2013.
EMBO encourages use of the CC-BY licence. The CC-BY licence facilitates the sharing of scientific information, while mandating citation of the source. This is particularly important for academic re-use of the data, such as for systematic literature analysis.
Under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License, users are free to share (copy, distribute and transmit) and to adapt (edit, rewrite or remix) the contribution under the following conditions (see full legal code at http://creativecommons.org/licenses/by-nc-sa/3.0/):
- Attribution. Users must attribute the contribution in the manner specified by the author or licensor (but not in any way that suggests that they or their use of the contribution is endorsed by the author or licensor).
- NonCommercial. Users may not use this work for commercial purposes.
- Share Alike. If users alter, transform, or build upon this work, they may distribute the resulting work only under the same or similar licence to this one.
Under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License, users are free to share (copy, distribute and transmit) the contribution under the following conditions (see full legal code at http://creativecommons.org/licenses/by-nc-nd/3.0/):
- Attribution. Users must attribute the contribution in the manner specified by the author or licensor (but not in any way that suggests that they or their use of the contribution is endorsed by the author or licensor).
- NonCommercial. Users may not use this contribution for commercial purposes.
- No derivative works. Users may not alter, transform, or build upon this work.
None of these Creative Commons Licence impairs or restricts the author's moral rights. Additionally, the following terms hold:
- For any reuse or distribution, users must make clear to others the license terms of this work, preferably using a link to the Creative commons webpage
- Any of the above conditions can be waived if users get permission from the copyright holder.
Please note that any file labeled "Source Data", "Dataset" or "Resource" is released under a Creative Commons CC0 1.0 Universal Licence (legal code at http://creativecommons.org/publicdomain/zero/1.0). This allows unrestricted re-use without the explicit requirement of attribution. We encourage attribution where this is warranted by good scholarly practice.
Digital Object Identifier
EMBO Press and its publishers assign a unique digital object identifier (DOI) to every article it publishes. The DOI initiative is an international effort for electronic content identification and is guided by the International DOI Foundation, composed primarily of academic publishers and societies. The DOI appears on the title page of the article. It is assigned after the article has been accepted for publication and persists throughout the lifetime of the article. It is important to include the article's DOI in the reference, as volume and page information is not always available for articles published online.
Help and Contact
If you need additional help, you can click on the help signs (icon) spread throughout the system. A help dialogue will pop up with context sensitive help. Should further assistance be required, then please contact MTS help. For questions regarding our policies and guidelines, please contact The EMBO Journal editorial office (email@example.com).


text:
Makin' Bacon with Chef Rusty Bowers of Atlanta's Pine Street Market
October 2, 2013
Earlier this summer I traveled to Georgia for the Atlanta Food & Wine Festival, the ultimate celebration of Southern food and culture. In between countless tastings and cooking demos conducted by many of the South's best barbecue cooks and professional chefs, I sat down with Chef Rusty Bowers of Pine Street Market in Atlanta to discuss one of my favorite topics – bacon – in between some very, very tasty pickled vegetables, terrines and so on and so on.
Here's a quick video with Rusty as he explains how they cure and slow smoke the pork belly pictured in the image above as well as his recipe for the cure.
House Cured and Smoked Bacon
Recipe Courtesy of Chef Rusty Bowers of Pine Street Market
(makes approximately 10lbs of bacon)
One full pork belly (available at many butcher stores, from local and online pig farmers and ethnic markets)
4 oz kosher salt
8 oz dark brown sugar
1 tsp pink salt
1. Skin the belly, if needed, and cut horizontally to make two equal pieces. Rub with the dry cure (a combination of the Kosher salt, brown sugar and pink salt), place into a large plastic zipper bag, and stack them on top of each other in a casserole dish or plastic container. Put it in the fridge.
2. Every day or so flip the belly and make sure the liquid gets evenly spread. Cure for 8 days.
3. Rinse the belly in cool water and return to the fridge uncovered for one day.
4. Cold smoke them to an internal temp of 140 degrees (I use a probe themometer) for 7-8 hours. I use a mix of Applewood chips and Pecan or Oak chips but most hard woods will do.
5. Cool the bellies to below 35 degrees and then slice. The bacon will keep in the fridge for 3 weeks or freeze for 6 months.
Thanks, Chef, and I'll definitely see you again during my next visit to Atlanta!
- Clint Cantwell, Grilling.com Editor